Status:
COMPLETED
Study to Evaluate the Safety of Twice Daily Oral Carvedilol
Lead Sponsor:
Shaddy, Robert, M.D.
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Congestive Heart Failure
Eligibility:
All Genders
1-17 years
Phase:
PHASE3
Brief Summary
The objective of this study is to evaluate the long-term safety of carvedilol in pediatric patients with chronic heart failure, who completed the Pediatric Carvedilol Study 321. Carvedilol will be pro...
Detailed Description
This open-label, uncontrolled, extension study is designed to assess the long-term safety of carvedilol in pediatric patients with heart failure and includes the following phases: 1. Screening Phase ...
Eligibility Criteria
Inclusion
- Male or female patients with chronic symptomatic congestive heart failure (CHF) due to systemic ventricular systolic dysfunction, who are receiving standard heart failure therapy and have successfully completed the maintenance phase of the Pediatric Carvedilol Study 321.
- Parent or guardian of patient able and willing to give written informed consent. The written assent from children \> 9 years of age is also required.
Exclusion
- A patient who, in the opinion of the investigator, would not benefit from open-label carvedilol.
- A patient who, in the opinion of the investigator, is incapable of cooperating with the requirements of this study.
- A patient treated with the following medications at the time of entry in the study:
- Monoamine oxidase (MAO) inhibitors;
- Calcium entry blockers;
- α- blockers, or labetalol;
- Disopyramide, flecainide, encainide, moricizine, propafenone;
- Intravenous inotropes such as dobutamine or intravenous vasodilator agents such as amrinone or milrinone;
- Intravenous CHF medications (e.g. diuretics, digoxin);
- Beta-blockers, other than double-blind carvedilol.
- Uncorrected primary obstructive or severe regurgitative valvular disease, nondilated (restrictive) or hypertrophic cardiomyopathy, or significant systemic ventricular outflow obstruction.
- A patient with any of the following contra-indications to beta-blocker therapy:
- Heart rate \< 2nd percentile for age;
- Unacceptable blood pressure. Sitting (supine in infants) systolic blood pressure must be \> 85 mm Hg in teens; \>75 mm Hg in school-aged children; and \>65 mm Hg in infants;
- Sick sinus syndrome, second or third degree atrioventricular (AV) block, unless treated with a permanent pacemaker;
- History or current clinical evidence of moderate-to-severe obstructive pulmonary disease or reactive airway diseases (e.g., asthma) requiring therapy;
- Unstable insulin-dependent diabetes mellitus.
- Renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance index \> 6 Wood units m2) unresponsive to vasodilator agents such as oxygen, nitroprusside, or nitric oxide
- A patient with any one of these general exclusion criteria:
- Significant renal (serum creatinine \> 2.0), hepatic (serum AST and/or ALT \> 3 times upper limit of normal), gastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medications;
- Endocrine disorders such as pheochromocytoma, active hyperthyroidism and untreated hypothyroidism;
- Any illness other than heart failure that may limit survival within 1 year (e.g. neoplasm);
- Girls of childbearing potential who are pregnant or sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device \[IUD\] or oral contraceptives).
- A patient who received any investigational drug within the preceding 30 days except blinded medication in Pediatric Carvedilol Study 321. An investigational drug is defined as any agent (placebo or drug) dispensed as part of a research study.
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00129363
Start Date
January 1 2002
End Date
January 1 2006
Last Update
December 25 2008
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Mattel Children's Hospital at UCLA
Los Angeles, California, United States, 90025
2
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
3
Stanford University
Palo Alto, California, United States, 94303
4
University of Colorado
Denver, Colorado, United States, 80218